Bridge Biotherapeutics, Inc. (KOSDAQ: 288330)

Bridge Biotherapeutics Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	7,936	14,183	7,942	8,200	20,943	64,087
Short-Term Investments	1,200	6,000	39,500	29,000	37,000	-0
Trading Asset Securities	-	-	3,852	5,928	-	5,069
Cash & Short-Term Investments	9,136	20,183	51,295	43,128	57,943	69,157
Cash Growth	-69.50%	-60.65%	18.94%	-25.57%	-16.21%	772.17%
Accounts Receivable	-	-0	-	-	572.25	-
Other Receivables	222.39	647.21	904.91	365.75	1,171	3,084
Receivables	222.39	647.21	904.91	365.75	1,743	3,084
Inventory	-	-	-	-	-	1,933
Prepaid Expenses	152.66	217.98	274.3	305.32	313.24	88.6
Other Current Assets	171.55	683.25	2,483	627.33	304.74	4,448
Total Current Assets	9,683	21,731	54,957	44,426	60,304	78,710
Property, Plant & Equipment	3,679	4,287	3,784	664.25	829.58	645.18
Long-Term Investments	740.73	890.53	470.01	94.06	0	0
Goodwill	2,888	3,899	-	-	-	-
Other Intangible Assets	2,756	226.84	131.89	179.22	223.78	271.91
Long-Term Deferred Charges	85.24	85.24	-	-	-	-
Other Long-Term Assets	1,521	1,564	2,112	1,293	2,153	109.63
Total Assets	21,353	32,683	61,455	46,657	63,510	79,737
Accrued Expenses	194.11	330.51	142.66	119.58	105.07	247.23
Current Portion of Leases	1,132	1,043	993.06	172.93	168.14	152.05
Current Unearned Revenue	-	-	-	1,076	-	3,773
Other Current Liabilities	4,860	9,002	6,359	2,188	782.26	535.5
Total Current Liabilities	6,186	10,375	7,494	3,556	1,055	4,708
Long-Term Leases	2,004	2,504	2,016	53.63	226.56	10.96
Long-Term Unearned Revenue	-	-	-	-	3,000	-
Other Long-Term Liabilities	84.78	83.22	80.17	0	-0	0
Total Liabilities	8,809	12,963	9,590	3,610	4,282	4,719
Common Stock	12,237	11,334	9,948	9,854	9,591	3,113
Additional Paid-In Capital	124,989	122,612	115,998	71,820	65,537	120,495
Retained Earnings	-140,793	-129,718	-87,397	-45,697	-19,419	-51,363
Comprensive Income & Other	13,437	13,193	10,945	7,071	3,519	2,773
Total Common Equity	9,871	17,421	49,494	43,047	59,228	75,018
Minority Interest	1,182	419.15	-	-	-	-
Shareholders' Equity	12,544	19,720	51,865	43,047	59,228	75,018
Total Liabilities & Equity	21,353	32,683	61,455	46,657	63,510	79,737
Total Debt	3,137	3,547	3,009	226.56	394.69	163.02
Net Cash (Debt)	5,999	16,636	48,286	42,901	57,548	68,994
Net Cash Growth	-74.15%	-65.55%	12.55%	-25.45%	-16.59%	-
Net Cash Per Share	225.36	674.63	2028.30	1830.30	2517.32	5931.23
Filing Date Shares Outstanding	24.47	27.2	23.88	23.65	23.02	22.41
Total Common Shares Outstanding	24.47	27.2	23.88	23.65	23.02	22.41
Working Capital	3,496	11,356	47,462	40,870	59,249	74,002
Book Value Per Share	403.30	640.45	2073.00	1820.27	2573.19	3347.50
Tangible Book Value	4,226	13,295	49,363	42,868	59,004	74,746
Tangible Book Value Per Share	172.69	488.76	2067.48	1812.69	2563.46	3335.37
Machinery	1,136	1,173	929.29	724.31	558.1	503.19
Construction In Progress	-	-	234.4	-	-	-

Source: S&P Capital IQ. Standard template. Financial Sources.